logo-loader
VolitionRx

VolitionRx well funded as it advances development of its novel cancer tests

VolitionRx Limited (NYSEAmerican:VNRX) CEO Cameron Reynolds brings Proactive's Andrew Scott up to date on developments with their cancer blood tests as well as discussing the group's 2018 results.

As of the end of December, Volition's cash position stood at $13.4 million - up from $10.1 million at the close of 2017.

Reynolds says continued development of their Nu.Q Capture and Nu.Q Vet products coupled with the strengthening of the company's product pipeline beyond colorectal cancer will help them generate early revenue.

Quick facts: VolitionRx

Price: $4.18

Market: NYSEMKT
Market Cap: $171.76 m
Follow

Watch

VolitionRx well positioned as it enters Q2 after strengthening balance sheet

Cameron Reynolds, chief executive of VolitionRx Limited (NYSE AMERICAN:VNRX), tells Proactive London's Andrew Scott they're in a good place after again strengthening the balance sheet in recent weeks with a further $5 million in warrants exercised for cash. ''Total cash in hand that gives...

on 9/5/19

2 min read

;